Interview
Covid-19: Bill Gates predicts the end of the pandemic
- Multiple vaccine candidates are scheduled to enter Phase III trials by the end of September, with expectations that leading efforts will achieve 80% to 90% efficacy in blocking transmission and sickness.
- The current vaccine pipeline is deemed sufficient to meet demand, requiring no additional constructs beyond the existing candidates from AstraZeneca, Johnson & Johnson, Novavax, and Sanofi.
- Global deployment requires billions of dollars in financing, estimated at $10 billion to $12 billion for developing nations at a marginal cost of $2 to $3 per dose, to prevent trillions in economic damage.
- The United States is credited with accelerating development via BARDA, with projections that its manufacturing capacity and potential supplemental legislation could help end the pandemic by late 2021, with possible spillover into 2022.
- Models suggest that a global vaccination rate of 30% to 40%, combined with natural immunity and cross-protection, may halt exponential viral spread, while herd immunity could be reached at rates between 30% and 60% depending on the high-end efficacy of specific vaccines.
- While efficacy for the elderly is critical, certain populations including pregnant women and individuals with specific medical conditions may be excluded from initial vaccination protocols.
- Emerging markets face continued severe economic and health risks due to reliance on commodity prices and borrowing limits, with the poorest nations expected to suffer the most despite potential government system overload and corruption risks.
- Concerns exist regarding declining multilateral cooperation amidst rising global needs, which could leave citizens in poorer countries without adequate support.